Industry

KGK to conduct Phase II clinical trial to test the efficacy of psilocybin on treatment resistant PTSD VANCOUVER, British Columbia–(BUSINESS WIRE)–$KONEF #ketamine–Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital … [Read more…]

The Genomic Test Demonstrated 100 Percent Sensitivity and 100 Percent Specificity for MTC SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) today announced that new clinical validation data published online in Thyroid show that the company’s RNA sequencing-based Afirma Medullary Thyroid Cancer (MTC) Classifier demonstrated high sensitivity and specificity in identifying MTC among pre-operative thyroid … [Read more…]

CHICAGO–(BUSINESS WIRE)–Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that on July 19, 2022, it received a letter from the Office of General Counsel of The Nasdaq Stock Market … [Read more…]

MENLO PARK, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its second quarter 2022 financial results on Wednesday, August 3, 2022. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. … [Read more…]

BOULDER, Colo.–(BUSINESS WIRE)–$CLVS–Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2022 financial results and provide an update on its clinical development programs and regulatory and business outlook on Monday, August 8, 2022, before the open of the US financial markets. Clovis’ senior management will host a conference call and live audio webcast at … [Read more…]

PASADENA, Calif.–(BUSINESS WIRE)–$arwr–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 4, 2022, at 4:30 p.m. ET to discuss its financial results for the fiscal 2022 third quarter ended June 30, 2022. Conference Call and Webcast Details Investors may access a live audio webcast on the … [Read more…]

Company Remains Focused on Finding a Licensee for This Proprietary Cyclosporine Platform and is Encouraged by the Significant Interest to Date MISSION VIEJO, Calif.–(BUSINESS WIRE)–Today, Wellspring Ophthalmics, a Mission Viejo-based development stage eye care pharmaceutical company focused on innovating an improved, effective dry eye therapy, announces receiving its second patent for a novel cyclosporine dry … [Read more…]

TORONTO–(BUSINESS WIRE)–Tomorrow, July 21st, union leaders from SEIU Healthcare and CUPE/OCHU, which together represent 70,000 hospital staff, will be holding a virtual press conference to call on hospital CEOs for answers and real transparency into the staffing crisis amidst the growing wave of emergency room closures across the province. This is a dire moment that … [Read more…]

Launch represents the company’s eighth commercial release within its line of Tranquil™ interbody fusion implants SALT LAKE CITY–(BUSINESS WIRE)–#compliantmechanisms–Nexus Spine, a developer of biomechanically-advanced solutions for spinal pathologies, today announced the beta launch of its Stable-C™ cervical interbody fusion implants featuring integrated anchoring blades. The limited release adds to the company’s growing line of Tranquil™ … [Read more…]

SAN FRANCISCO–(BUSINESS WIRE)–California Society of Dermatology and Dermatologic Surgery (CalDerm), the leading voice for Dermatologists, announced the launch of the Firefighter Skin Cancer Prevention Screening Program in California in partnership with the Firefighters Cancer Support Network. CalDerm, alongside our partners at the Firefighter Cancer Support Network, is pleased to utilize the framework built by their … [Read more…]